Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone

被引:6
|
作者
Gavin, Kathleen M. [1 ,2 ]
Shea, Karen L. [1 ,2 ]
Gibbons, Ellie [1 ]
Wolfe, Pamela [3 ]
Schwartz, Robert S. [1 ,2 ]
Wierman, Margaret E. [4 ]
Kohrt, Wendy M. [1 ,2 ]
机构
[1] Univ Colorado, Div Geriatr Med, Sch Med, Anschutz Med Campus, Aurora, CO USA
[2] Vet Affairs Eastern Colorado Heath Care Syst, Educ & Clin Ctr, Geriatr Res, Denver, CO USA
[3] Univ Colorado, Dept Preventat Med & Biostat, Anschutz Med Campus, Aurora, CO USA
[4] Univ Colorado, Div Endocrinol Metab & Diabet, Anschutz Med Campus, Aurora, CO USA
关键词
central adiposity; cortisol; estradiol; gonadotropin-releasing hormone agonist; menopause; BODY-FAT DISTRIBUTION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; CORTISOL AWAKENING RESPONSE; LEUPRORELIN ACETATE DEPOT; POSTMENOPAUSAL WOMEN; MENSTRUAL-CYCLE; ESTRADIOL TREATMENT; ENERGY-EXPENDITURE; METABOLIC SYNDROME; BINDING GLOBULIN;
D O I
10.1152/ajpendo.00221.2017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sex honnones appear to play a role in the regulation of hypothalamic-pituitary-adrenal (HPA) axis activity. The objective was to isolate the effects of estradiol (E-2) on central activation of the HPA axis. We hypothesized that the HPA axis response to corticotropin-releasing hormone (CRH) under dexamethasone (Dex) suppression would be exaggerated in response to chronic ovarian hormone suppression and that physiologic E-2 add-back would mitigate this response. Thirty premenopausal women underwent 20 wk of gonadotropin-releasing hormone agonist therapy (GnRH(AG)) and transderma] E-2 (0.075 mg per day, GnRH(AG), + E-2, n = 15) or placebo (PL) patch (GnRH(AG) + PL, n = 15). Women in the GnRH(AG) + PL and GnRH(AG) + E-2 groups were of similar age (38 (SD 5) yr vs. 36 (SD 7) yr) and body mass index (27 (SD 6) kg/m(2) vs. 27 (SD 6) kg/m(2)). Serum E-2 changed differently between the groups (P = 0.01); it decreased in response to GnRH(AG) + PL (77.9 +/- 17.4 to 23.2 +/- 2.6 pg/ml; P = 0.008) and did not change in response to GnRH(AG) + E-2 (70.6 +/- 12.4 to 105 +/- 30.4 pg/ml; P = 0.36). The incremental area under the curve (AUC(INC)) responses to CRH were different between the groups for total cortisol (P = 0.03) and cortisone (P = 0.04) but not serum adrenocorticotropic hormone (ACTH) (P = 0.28). When examining within-group changes. GnRH(AG) + PL did not alter the HPA axis response to Dex/CRH, but GnRH(AG) + E-2 decreased the AUC(INC) for ACTH (AUC(INC), 1,623 +/- 257 to 1,211 +/- 236 pg/ml center dot min, P = 0.004). cortisone (1.795 +/- 367 to 1.090 +/- 281 ng/ml center dot min, P = 0.009), and total cortisol (7.008 +/- 1.387 to 3,893 +/- 1,090 ng/ml center dot min, P = 0.02). Suppression of ovarian hormones by GnRH(AG) therapy for 20 wk did not exaggerate the HPA axis response to CRH, but physiologic E-2 add-back reduced HPA axis activity compared with preintervention levels.
引用
收藏
页码:E316 / E325
页数:10
相关论文
共 50 条
  • [31] REGULATION OF CORTICOTROPIN-RELEASING HORMONE RECEPTORS AND HYPOTHALAMIC PITUITARY-ADRENAL AXIS RESPONSIVENESS DURING COLD STRESS
    HAUGER, RL
    AGUILERA, G
    JOURNAL OF NEUROENDOCRINOLOGY, 1992, 4 (05) : 617 - 624
  • [32] Effects of Corticotropin-Releasing Factor 1 Receptor Antagonism on the Hypothalamic-Pituitary-Adrenal Axis of Rodents
    Gehlert, Donald R.
    Cramer, Jeffrey
    Morin, S. Michelle
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (03): : 672 - 680
  • [33] EFFECTS OF PYRIDOSTIGMINE, CORTICOTROPIN-RELEASING HORMONE AND GROWTH HORMONE-RELEASING HORMONE ON THE PITUITARY-ADRENAL AXIS AND ON GROWTH-HORMONE SECRETION IN DEMENTIA
    MURIALDO, G
    FONZI, S
    TORRE, F
    COSTELLI, P
    SOLINAS, G
    TOSCA, P
    DIPAOLO, E
    PORRO, S
    ZERBI, F
    POLLERI, A
    NEUROPSYCHOBIOLOGY, 1993, 28 (04) : 177 - 183
  • [34] Variability in the secretion of corticotropin-releasing hormone, adrenocorticotropic hormone and cortisol and understandability of the hypothalamic-pituitary-adrenal axis dynamics-a mathematical study based on clinical evidence
    Bairagi, N.
    Chatterjee, Samrat
    Chattopadhyay, J.
    MATHEMATICAL MEDICINE AND BIOLOGY-A JOURNAL OF THE IMA, 2008, 25 (01): : 37 - 63
  • [35] Depression in women treated with a gonadotropin-releasing hormone agonist
    Toren, P
    Dor, J
    Mester, R
    Mozes, T
    Blumensohn, R
    Rehavi, M
    Weizman, A
    BIOLOGICAL PSYCHIATRY, 1996, 39 (05) : 378 - 382
  • [36] Effects of gonadotropin-releasing hormones, corticotropin-releasing hormone, and vasopressin on female sexual behavior
    Schiml, PA
    Rissman, EF
    HORMONES AND BEHAVIOR, 2000, 37 (03) : 212 - 220
  • [37] A COMPARISON OF THE EFFECTS OF HUMAN AND OVINE CORTICOTROPIN-RELEASING HORMONE ON THE PITUITARY-ADRENAL AXIS
    TRAINER, PJ
    FARIA, M
    NEWELLPRICE, J
    BROWNE, P
    KOPELMAN, P
    COY, DH
    BESSER, GM
    GROSSMAN, AB
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (02): : 412 - 417
  • [38] RESPONSE TO PULSATILE GONADOTROPIN-RELEASING HORMONE IN HYPOTHALAMIC HYPOGONADISM
    GUTAI, JP
    DANEMAN, D
    FOLEY, TP
    ACTA ENDOCRINOLOGICA, 1979, 91 : 137 - 137
  • [39] Androgens alter corticotropin releasing hormone and arginine vasopressin mRNA within forebrain sites known to regulate activity in the hypothalamic-pituitary-adrenal axis
    Viau, V
    Soriano, L
    Dallman, MF
    JOURNAL OF NEUROENDOCRINOLOGY, 2001, 13 (05) : 442 - 452
  • [40] MODULATION OF PITUITARY GONADOTROPIN RESPONSE TO GONADOTROPIN-RELEASING HORMONE BY ESTRADIOL
    KEYE, WR
    JAFFE, RB
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1974, 38 (05): : 805 - 810